Curis, Inc.
CRIS Healthcare Biotechnology
Curis, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $9.4 million, down 13.4% from fiscal 2024. In the quarter to June 2026, revenue fell 66.0%, EPS grew 70.4% and free cash flow fell 20.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
Follow CRIS
Curis, Inc. (CRIS) Altman Z-score
Curis, Inc.'s Altman Z-score for fiscal 2025 is −87.83, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2025 | −87.83 | (42.93) |
| FY2024 | −44.90 | (22.60) |
| FY2023 | −22.30 | (7.41) |
| FY2022 | −14.89 | (9.14) |
| FY2021 | −5.75 | (2.43) |
| FY2020 | −3.32 | 38.12 |
| FY2019 | −41.44 | (3.03) |
| FY2018 | −38.41 | (20.33) |
| FY2017 | −18.08 | (2.44) |
| FY2016 | −15.64 | (9.42) |
How fiscal 2025’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | (0.36) | — | −0.43 | |
| Retained earnings / total assets | (62.48) | — | −87.47 | |
| EBIT / total assets | (0.29) | — | −0.94 | |
| Market value of equity / total liabilities | 0.90 | — | 0.54 | |
| Sales / total assets | 0.47 | — | 0.47 | |
| Altman Z-score | Distress zone | −87.83 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −207.55 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| BPTH Bio-Path Holdings, Inc. compare | 6.9× |
| SPRC SciSparc Ltd. compare | −18.7× |
| LYRA Lyra Therapeutics, Inc. compare | −19.4× |
| CYTOF Altamira Therapeutics Ltd. compare | −60.3× |
| CRIS Curis, Inc. | −87.8× |
| BBLG Bone Biologics Corp. compare | — |
| PTIX Atrinsic Inc. compare | — |
| ZVSA ZyVersa Therapeutics, Inc. compare | — |
| MNTRQ 9 Meters Biopharma, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets